11/21
01:34 pm
rlmd
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
11/19
09:14 am
rlmd
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
11/19
09:00 am
rlmd
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Medium
Report
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
11/14
07:39 am
rlmd
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]
Low
Report
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]
11/14
07:30 am
rlmd
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
Low
Report
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
11/8
02:48 am
rlmd
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
11/7
04:32 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/7
04:23 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/7
04:10 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/4
04:30 pm
rlmd
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Low
Report
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
9/17
08:07 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock, up previously from $3.50.
Low
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock, up previously from $3.50.
9/16
09:36 pm
rlmd
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Medium
Report
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
9/13
06:34 am
rlmd
Insider Spends US$395k Buying More Shares In Relmada Therapeutics [Yahoo! Finance]
Medium
Report
Insider Spends US$395k Buying More Shares In Relmada Therapeutics [Yahoo! Finance]
9/5
09:29 am
rlmd
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Medium
Report
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm